# **Special Issue**

# Gene Therapy for Neurodegenerative Diseases

## Message from the Guest Editor

Neurodegenerative disorders are a devastating burden for patients and their families. Many of these diseases progress rapidly, thereby robbing the patients of key functions including cognition, vision, hearing, and movement. There is an urgent need for the development of therapeutics to slow down or halt the progression of neurodegeneration. Gene therapy approaches using adeno-associated viral vectors (AAVs) are emerging as a promising strategy to target the nervous system and hold the potential for long-lasting benefit with only a single treatment. Many innovative strategies targeting either underlying mutations that cause neurodegeneration or interfering with pathways involved in disease progression are currently under development. This Special Issue is dedicated to gene therapy approaches for neurodegenerative diseases. It will cover research articles on therapeutic gene therapy strategies for various disorders affecting the nervous and neuromuscular systems. Comprehensive reviews providing an overview over gene therapy studies for neurodegenerative disorder.

#### **Guest Editor**

Dr. Kathrin Mever

Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA

### Deadline for manuscript submissions

closed (15 January 2020)



# Brain <u>Scien</u>ces

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.8
Indexed in PubMed



mdpi.com/si/28739

Brain Sciences MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 brainsci@mdpi.com

mdpi.com/journal/ brainsci





# Brain Sci<u>ences</u>

an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

## **Editor-in-Chief**

Prof. Dr. Stephen D. Meriney

Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260. USA

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.9 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

### **Recognition of Reviewers:**

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

